Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative

1 . A molecular crystal form of a compound having Formula I, characterized by an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 7.44, 14.80, 16.64, and 23.04±0.2°

2 . The molecular crystal form of compound having Formula I according to claim 1 , wherein the XRPD spectrum further comprises a peak at 2θ angles of 23.36±0.2°.

3 . The molecular crystal form of compound having Formula I according to claim 1 , wherein said molecular crystal is formed by subjecting an aqueous suspension comprising a compound having Formula I to an autoclaving condition at 121-125° C., about 100-120 kPa above atmospheric pressure, for 30 minutes to 10 hours, under a closed atmosphere generated by said aqueous suspension.

4 . The molecular crystal form of compound having Formula I according to claim 1 , wherein said molecular crystal is substantially incapable of changing in crystalline structure, as exhibited by a plurality of peaks in an X-ray powder diffraction (“XRPD”) spectrum, upon storage at normal room conditions of temperature, pressure, and humidity after at least 1 month, as exhibited by a relative change of less than about 5 percent in the peak height of the highest peak in its XRPD spectrum, wherein said normal room conditions of temperature, pressure, and humidity are 20-28° C., 95-105 kPa, and 20-80% relative humidity.

5 . A pharmaceutical composition comprising a molecular crystal form of a compound having Formula I,

wherein said molecular crystal is characterized by an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 7.44, 14.80, 16.64, and 23.04±0.2°.

6 . The pharmaceutical composition of claim 5 , further comprising an ophthalmically acceptable carrier, wherein said composition is suitable for intravitreal administration.

7 . A method for treating or controlling a disease resulting from a pathological angiogenesis, said method comprising administering to a subject, who suffers from, or is at risk of developing, said disease, a pharmaceutical composition comprising a molecular crystal form of a compound having Formula I, characterized by an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 7.44, 14.80, 16.64, and 23.04±0.2°

8 . The method of claim 7 , wherein said pharmaceutical composition further comprises an ophthalmically acceptable carrier.

9 . The method of claim 8 , wherein said disease is selected from the group consisting of wet age-related macular degeneration, dry age-related macular degeneration, macular edema, diabetic retinopathy, and combinations thereof.

10 . The method of claim 9 , wherein said disease comprises wet age-related macular degeneration.

11 . The method of claim 10 , wherein said pharmaceutical composition is administered intravitreally to said subject.

12 . A method of producing a molecular crystal of a compound having Formula I,

the method comprising subjecting a suspension comprising a compound having Formula I to an autoclaving condition at 121-125° C., about 100-120 kPa above atmospheric pressure, for 30 minutes to 10 hours, under a closed atmosphere generated by said aqueous suspension, wherein said molecular crystal is characterized by an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 7.44, 14.80, 16.64, and 23.04±0.2°.

13 . The method of claim 12 , wherein said molecular crystal is substantially incapable of changing in crystalline structure, as exhibited by a plurality of peaks in an X-ray powder diffraction (“XRPD”) spectrum, upon storage at normal room conditions of temperature, pressure, and humidity after at least 1 month, as exhibited by a relative change of less than about 5 percent in the peak height of the highest peak in its XRPD spectrum, wherein said normal room conditions of temperature, pressure, and humidity are 20-28° C., 95-105 kPa, and 20-80% relative humidity.